ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System

Novel hybrid LTS-HTS superconducting magnet enables high-resolution for liquids and solids ultra-high field NMR research in biomolecular and advanced materials sciences

At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world’s first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. This first-of-a-kind ultra-high field magnet and spectrometer pushes the boundaries of what is possible in the field of NMR research and opens a new chapter of ultra-high field NMR with even higher dispersion and resolution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407030056/en/

The 1.3 GHz first-of-a-kind high-resolution UHF NMR spectrometer in Bruker’s UHF facility in Fällanden, Switzerland

The 1.3 GHz first-of-a-kind high-resolution UHF NMR spectrometer in Bruker’s UHF facility in Fällanden, Switzerland

Building on the success of its 1.0-1.2 GHz systems, Bruker's 1.3 GHz NMR spectrometer offers unprecedented resolution and sensitivity, enabling scientists to study complex biomolecular systems and advanced materials in greater detail. The first-of-a-kind superconducting and persistent standard-bore NMR magnet has a field strength of 30.5 Tesla (T) and incorporates a novel ReBCO high-temperature superconductor (HTS) insert, generating even higher magnetic fields. The novel 1.3 GHz magnet extends Bruker’s innovative LTS-HTS hybrid magnet architecture. Despite higher field, the 1.3 GHz magnet maintains the same physical dimensions and cryogen consumption as Bruker’s 1.2 GHz magnets, with a slightly increased stray field radius.

Applications testing at 1.3 GHz proton frequency was conducted using five different NMR probe configurations: a 3 mm TXI liquids room-temperature probe, a 5 mm TXO liquids CryoProbe, a 111 kHz (0.7 mm) HCN solid-state magic-angle spinning (MAS) probe, a 42 kHz (1.9 mm) solid-state MAS probe optimized for materials research, and the new ultra-fast spinning 160 kHz (0.4 mm) HCN solid-state MAS probe, the latest innovations in solid-state NMR for the study of biological systems. These tests confirmed the applicability of the 1.3 GHz NMR first-of-a-kind spectrometer, yielding high-resolution liquids and solids NMR spectra at 1.3 GHz. The results demonstrated increased resolution and sensitivity, highlighting the potential for groundbreaking biomolecular and materials research.

The increased magnet field strength particularly benefits spectroscopy of bio-macromolecules lacking dispersion, such as carbohydrates, glycoproteins, RNA, and intrinsically disordered proteins (IDPs) without secondary and tertiary structures. Direct 13C and 15N detection of IDPs shows the gain of 1.3 GHz sensitivity, offering new strategies to obtain atomic resolution with respect to dynamics and function. In solid state, UHF NMR is crucial for studying quadrupolar nuclei, where the increased field leads to narrower spectral lines due to the inverse relationship between the breadth of the quadrupolar pattern and the field strength. Additionally, the chemical shift interaction grows linearly with the field, enhancing the ability to measure chemical shift tensors using UHF systems. These technological advancements are driving exciting breakthroughs in both material science and biological science.

"Achieving 1.3 GHz is yet another testament to Bruker's commitment to innovation," said Dr. Falko Busse, President of the Bruker BioSpin Group. "We are confident that our high-resolution GHz-class NMRs enable researchers to advance their scientific understanding of complex biomolecular systems, and also provide substantial benefits for advanced materials science research, particularly in molecules and materials incorporating chemical elements with quadrupolar and low-gamma nuclei."

"We are thrilled to be among the first scientists to experiment with the 1.3 GHz NMR spectrometer," said Dr. Takanori Kigawa from the Center for Integrative Medical Sciences of the RIKEN Yokohama Institute, Japan, a leading researcher in structural biology. "The gain in resolution and sensitivity is truly remarkable. We were blown away by the level of detail we observe in our protein and nucleic acid samples, which opens up new opportunities for our research in biological systems.”

Dr. Pierre Florian, materials science researcher at CEMHTI-CNRS Orléans, France, who ran solid-state samples for characterization, stated: "I am very impressed with the first experiments carried out on the 1.3 GHz spectrometer. This technology dramatically improves our ability to resolve different types of atomic environments in complex materials and also offers unprecedented sensitivity."

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Investor Contact:

Joe Kostka

Director - Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: Investor.Relations@bruker.com

Media Contact:

Markus Ziegler

Sr. Director and Head of Group Marketing

Bruker BioSpin

T: +49 172 373-3531

E: pr@bruker.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.